Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed

... of Appeals upheld the District Court's decision that JNJ's Bx Velocity and cypher Stent Systems infringe Boston Scientific's patent and that the patent is va...are gratified the appeals court upheld the finding that the BX Velocity and cypher stents infringe our patent and the patent is valid, and we are pleased the ...

Drug-Coated Stents Reduce Repeat Artery Procedures

.... A stent is a tiny tube placed into an artery or blood vessel to keep the vessel open. Only one coated stent -- Cordis Corp.'s sirolimus-coated cypher -- was available in 2003. Over a two-year follow-up period, 22.8 percent of the people in the bare-stent era required a repeat procedure to open a blo...

Experts Offer Clarity on Confusion Surrounding Stents

..., double the price of a bare-metal stent. In recent years, the Taxus and cypher drug-eluting stents have dominated the field, and conflicting studies compa...ospital, in Chicago. When it comes to drug-eluting stents, the Taxus and cypher models perform equally well, he said. "I think they are very similar," D...

Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent

...y announced three new partnership agreements. The first is with Cordis Europe that will enable Cordis to offer their customers Volcano IVUS for use in cypher drug-eluting stent procedures. The second was a marketing agreement with Siemens in Japan under which Siemens will begin selling their Artis and angio...

Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months

...ived from sales of Enbrel (in the United States and Canada), Altace and the cypher stent. Enbrel(R) continued to post strong revenue growth during the 2007 t...07 third quarter due to lower alliance revenue associated with sales of the cypher stent and Altace. For the 2007 first nine months, alliance revenue increase...

Study Finds Benefits With Drug-Coated Stents

...rcent getting the Cypher, which is coated with sirolimus and marketed by Cordis. Recent studies have found the risk of restenosis is lower with the cypher stent. Tu said his group has not yet looked for a product-to-product comparison. The study defined high risk as the presence of two of three risk f...

ENDEAVOR III Trial Reports Key Findings on New-generation Stent

...nal Endeavor stent (Medtronic, Minneapolis) or the cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL)....xible and is considered easier to implant than the cypher stent. However, at 8 months, the Endeavor stent fe...he inner diameter of the artery as compared to the cypher stent. At 12 months, clinical outcomes were equiva...

Stent’s Benefits Outweigh Disadvantage

...f drug-eluting stent should not be limited. The new drug-eluting stents are cypher and Taxus. There has been a 20% re-clogging in the case of the old stents, ...nt problems get reported. Sources from Cordis Corp which manufactures cypher stent do not fully agree with the findings of the study, as they contend th...

Cypher in Medical Technology

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

...based drug-eluting stents (DES), including Cordis' cypher (R) Stent and Medtronic's Endeavor (R) Stent. I...s as compared to those without diabetes. Both the cypher Stent and Endeavor Stent showed significant increa...d four DES brands: TAXUS Liberte, TAXUS Express, cypher and Endeavor. In total, the registry included 35,...

Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study

...h an abluminal biodegradable polymer coating, or a cypher Sirolimus-eluting DES with a durable polymer. In t...ensors DES, and 10.5 percent of patients given the cypher DES experienced a clinical adverse event that coul... that the Biosensors stent was non-inferior to the cypher stent. A favorable trend towards the Biosensors st...

OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial

...is a viable alternative to drug-eluting stents, which have raised many safety concerns among the interventional cardiology community. Unlike TAXUS and cypher that elute cytotoxic agents to inhibit neointimal proliferation, Genous attracts circulating endothelial progenitor cells to rapidly build a layer of ...

Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome

...as the lead investigator of this double-blinded clinical study of almost 1,500 patients treated with the Johnson & Johnson / Cordis drug-eluting cypher stent. The study was sponsored by Cordis, and findings were presented at TCT in 2006. ...

Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM)

...atients will be enrolled for a non-inferiority study of Genous vs. Taxus or cypher drug-eluting stents. In the TRIAS LR arm, approximately 1,250 patients will... days of clopidogrel post-procedure, while patients treated with a Taxus or cypher stent will receive at least six months of clopidogrel post-procedure. For ...

Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

...of any drug-eluting stent. The next version of sirolimus-eluting stent, the cypher SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The cypher SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary st...

Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

...of any drug-eluting stent. The next version of sirolimus-eluting stent, the cypher SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The cypher SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary st...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

...of any drug-eluting stent. The next version of sirolimus-eluting stent, the cypher SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The cypher SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary st...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

...of any drug-eluting stent. The next version of sirolimus-eluting stent, the cypher SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The cypher SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary st...

Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stent's Positive Clinical Profile

...vents - a composite safety measure of death, repeat procedures and myocardial infarction (MI) - was reported to be 9.3% for Endeavor and 11.6% for the cypher stent also studied in the ENDEAVOR III trial (p = 0.47). There was no statistically significant difference in the need for repeat procedures, or Targe...

Cypher in Medical Products

Cypher Sirolimus-eluting Coronary Stent

Description:... The cypher Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell sten...
Company:Cordis Corporation

Cypher Stent

Description:... The cypher Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell sten...
Company:Cordis Corporation

Cypher in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...pared to those without diabetes. Data for both the cypher and Endeavor stents indicated significant increase...ded four DES brands: TAXUS Liberte, TAXUS Express, cypher and Endeavor. In total, the registry included 35,4...her in the non-TAXUS stents. The sirolimus-eluting cypher and the zotorolimus-eluting Endeavor had higher re...

Boston Scientific Announces First Quarter Special Items

...il 2010 or later, from either Boston Scientific or J&J. "We were gratified the appeals court upheld the finding that the BX Velocity and cypher stents infringe our patent," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We believe this ruling has the potential to...

Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President

...e President of Sales and Marketing at Cordis Corporation where he oversaw the cardiovascular business including the market leading drug eluting stent, cypher (TM). Mr. Pinon received a bachelor's degree in biology from the University of Oregon . Terumo Heart, Inc. is a U.S. subsidiary of Terumo Co...

Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents

...fficacy data from clinical trials with the PROMUS, cypher and Endeavor stents but data from this registry wi... the PROMUS Stent and half will receive either the cypher or the Endeavor Stent to attain a 2:1:1 ratio of P...sel revascularization) at 12 months. The PROMUS, cypher and Endeavor Stents have previously been investiga...

Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year

...from sales of Enbrel (in the United States and Canada), Altace and the cypher stent. Product Highlights Enbrel(R) continued to post strong revenue g...e 2007 full year due to lower alliance revenue associated with sales of the cypher stent and Altace. The decrease was partially offset by higher sales of Enbr...

The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

...rior to labeling.

2. For details of the labeling method used, refer to the instructions supplied with CypHer5E NHS ester (PAI5401) or the cypher User Manual. For conjugation of CypHer5E NHS ester to anti-EGFR antibody we recommend a 20 M excess of CypHer5E NHS ester.

3. The final dy...

The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR

...and 450BP65 emission for Hoechst.

Conjugation of cypher 5 Mono NHS Ester to anti-EGFR antibody 1. Comm..., refer to the instructions supplied with CypHer5 Mono NHS Ester and/or the cypher User Manual. For conjugation of CypHer5 Mono NHS Ester to anti-EGFR antibod...

Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000

... Introduction cypher ™ 5, a pH sensitive dye, has shown utility in β2-adrenergic rece... Screening for 2-adrenergic receptor agonists using the pH-sensitive dye, cypher 5, and IN Cell Analyzer 3000, Amersham Biosciences, 11-0002-81.